M. Jabari: Radioprotection 2025, 60( 3), 277 – 284 283 between the biodistribution of 177 Lu-DOTATATE and 90 Y-DOTATATE. The differences include renal clearance
of 90 Y-DOTATATE that is less than 177 Lu-DOTATATE which leads to less accumulation of radiopharmaceutical in bladder, resulting in better capacity of the surrounding bladder and bladder tissue. Also, liver absorption is higher in 90 Y-DOTATATE compared to 177 Lu-DOTATATE. This high
absorption is considered a weakness in detecting liver metastases. Patient-specific dosimetry definitely will help to determine accurately amount of differences between these two tracers. Data gained from real patients imaging may lead also to determine how much total received dose is different for these two agents as well as organ doses.
5 Conclusion
Our results show that the absorbed dose falls down dramatically when 177 Lu-DOTATATE is employed instead of 90 Y-DOTATATE. The lower absorbed dose in patient body
may be another reason to put 177 Lu-DOTATATE in superiority for neuroendocrine tumor therapy. As a consequence, patients with a high BMI were exposed to more radiation than those with a low BMI. To prevent excessive dosage to patients, it is important to consider the relationship between body size and dose.
Funding
This article did not receive any specific funding.
Conflicts of interests
The authors report no conflict of interest.
Data availability statement
The author confirms that the data supporting the findings of this study are available within the article.
Ethics approval
Research does not involve human participants or animals Informed consent.
References
Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, Gärtner F, Rogenhofer S, Schäfers M. 2015. Essler Early side effects and first results of radioligand therapy with 177 Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 5: 1.
Alnaaimi M, Sulieman A, Alkhorayef M, Salah H, Alduaij M. 2021. Organs dosimetry in targeted radionuclide therapy. Radiat Phys Chem 188: 109668.
Capala J, Graves S, Scott A, Sgouros G, James S, Zanzonico P, Zimmerman BE. 2021. Dosimetry for radiopharmaceutical therapy: current practices and commercial resources. J Nucl Med 62: 3.
Carneiro LG, de Lucena EA, da Silva Sampaio C, Dantas AL, Sousa WO, Santos MS, Dantas BM. 2015. Internal dosimetry of nuclear medicine workers through the analysis of 131I in aerosols. Appl Radiat Isotopes 1: 70.
Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska- Guttmejer A, Jeziorski KG, Mikolajczak R, Pawlak D, Stepien K, Walecki J. 2010. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas( GEP-NETs): a phase II study. Ann Oncol 21: 787.
Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, et al. 2014. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas 43: 518.
Goddu SM. 1997. MIRD cellular S values: Self-absorbed dose per unit cumulated activity for selected radionuclides and monoenergetic electron and alpha particle emitters incorporated into different cell compartments. Society of Nuclear Medicine Vol. 1, Part2, Chap. 3, p. 150
Huizing DM, Verheij M, Stokkel MP. 2018. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res. 8: 1.
Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. 2011. Clinical results of radionuclide therapy of neuroendocrine tumours with 90 Y- DOTATATE and tandem 90 Y / 177 Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imag 38: 1788.
Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. 2011. Clinical results of radionuclide therapy of neuroendocrine tumours with 90 Y- DOTATATE and tandem 90 Y / 177 Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Molec Imag 38: 1788.
Lassmann M, Eberlein U, Gear J, Konijnenberg M, Kunikowska J. 2021. Dosimetry for radiopharmaceutical therapy: the European perspective. J Nucl Med 62: 737.
Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K., 2016. MIRD pamphlet no. 26: joint EANM / MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med 57: 151. Mattsson S. 2015. Patient dosimetry in nuclear medicine. Radiat
Protect Dosimetry 165: 416. Mittra ES. 2018. Neuroendocrine tumor therapy: 177Lu-DOTATATE.
Am J Roentgenol 211: 278.
Panta RK, Segars P, Yin FF, Cai J. 2012. Establishing a framework to implement 4D ICRP phantom for 4D radiotherapy research. J Cancer Res Therapeut 8: 565.
Parach AA, Rajabi H, Askari MA. 2011. Assessment of MIRD data for internal dosimetry using the GATE Monte Carlo code. Radiat Environ Biophys 50: 441.
Pinto GM, Bonifacio DA, de Sá LV, Lima LFC, Vieira IF, Lopes RT. 2020. A cell-based dosimetry model for radium-223 dichloride therapy using bone micro-CT images and GATE simulations. Phys Med Biol 65: 450. Potter CA. 2024. Internal dosimetry— a review. Health Phys 87: 455. Pasquier JL, Bourguignon M, Bertho JM. 2011. Une dialectique récurrente: des dangers aux risques des expositions aux rayonnements ionisants. Radioprotection. 2024 Dec 13; 59: 250.